Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway

[1]  Xiaolong Liu,et al.  A Prisma-compliant meta-analysis , 2018 .

[2]  J. Lang,et al.  The roles of metallothioneins in carcinogenesis , 2018, Journal of Hematology & Oncology.

[3]  Chih-Hung Hsu,et al.  Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. , 2016, Cancer letters.

[4]  W. Hur,et al.  Synergistic effects of CD44 and TGF-β1 through AKT/GSK-3β/β-catenin signaling during epithelial-mesenchymal transition in liver cancer cells. , 2016, Biochemical and biophysical research communications.

[5]  D. Tang,et al.  Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis , 2016, Hepatology.

[6]  F. Liu,et al.  Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1 , 2016, Oncotarget.

[7]  Qiang Li,et al.  Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models , 2016, Journal of Hematology & Oncology.

[8]  A. Jemal,et al.  Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.

[9]  Hui‐bao Long,et al.  Metallothionein ameliorates burn sepsis partly via activation of Akt signaling pathway in mice: a randomized animal study , 2015, World Journal of Emergency Surgery.

[10]  E. Eyal,et al.  High metallothionein predicts poor survival in glioblastoma multiforme , 2015, BMC Medical Genomics.

[11]  S. Zeng,et al.  Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. , 2015, World journal of hepatology.

[12]  G. Malaguarnera,et al.  Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies , 2014, BioMed research international.

[13]  Malay Shah,et al.  Targeting the Wnt/β-Catenin Signaling Pathway in Liver Cancer Stem Cells and Hepatocellular Carcinoma Cell Lines with FH535 , 2014, PloS one.

[14]  L. Cai,et al.  Metallothionein prevents intermittent hypoxia-induced cardiac endoplasmic reticulum stress and cell death likely via activation of Akt signaling pathway in mice. , 2014, Toxicology letters.

[15]  P. Malfertheiner,et al.  Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment , 2014, Gastrointestinal Tumors.

[16]  J. Wu,et al.  CD58, a novel surface marker, promotes self-renewal of tumor-initiating cells in colorectal cancer , 2014, Oncogene.

[17]  M. He,et al.  Effects of metallothionein-3 and metallothionein-1E gene transfection on proliferation, cell cycle, and apoptosis of esophageal cancer cells. , 2013, Genetics and molecular research : GMR.

[18]  P. Hou,et al.  Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway , 2013, BMC Cancer.

[19]  G. Liang,et al.  Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues , 2013, World Journal of Surgical Oncology.

[20]  L. Tang,et al.  Prognostic Significance of AMPK Activation and Therapeutic Effects of Metformin in Hepatocellular Carcinoma , 2013, Clinical Cancer Research.

[21]  Jun Yu,et al.  Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection , 2013, Journal of Translational Medicine.

[22]  K. Iguchi,et al.  Suppression of metallothionein 3 gene expression by androgen in LNCaP prostate cancer cells. , 2013, Biomedical reports.

[23]  George C Tseng,et al.  Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1 , 2013, The Journal of pathology.

[24]  Delong Liu,et al.  MEK and the inhibitors: from bench to bedside , 2013, Journal of Hematology & Oncology.

[25]  Hui-lai Miao,et al.  Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down‐regulation of YAP , 2013, Journal of cellular biochemistry.

[26]  X. Zhang,et al.  MicroRNA-520e suppresses growth of hepatoma cells by targeting the NF-κB-inducing kinase (NIK) , 2012, Oncogene.

[27]  Shinichirou Takahashi.  Molecular functions of metallothionein and its role in hematological malignancies , 2012, Journal of Hematology & Oncology.

[28]  Hua-mei Tang,et al.  Downregulation of metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue. , 2012, Biochimica et biophysica acta.

[29]  M. Chatterjee,et al.  A Review of Metallothionein Isoforms and their Role in Pathophysiology , 2011, World journal of surgical oncology.

[30]  Hyung Gyun Kim,et al.  Metallothionein‐2A overexpression increases the expression of matrix metalloproteinase‐9 and invasion of breast cancer cells , 2011, FEBS letters.

[31]  P. Tan,et al.  Silencing the Metallothionein‐2A Gene Induces Entosis in Adherent MCF‐7 Breast Cancer Cells , 2010, Anatomical record.

[32]  Kun Wu,et al.  Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. , 2010, Cancer research.

[33]  H. Yatani,et al.  Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice , 2010, Journal of Bone and Mineral Metabolism.

[34]  A. Naba,et al.  Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity. , 2009, International journal of oncology.

[35]  H. Pontes,et al.  Metallothionein and p-Akt proteins in oral dysplasia and in oral squamous cell carcinoma: an immunohistochemical study. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[36]  M. Kanda,et al.  Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. , 2009, International journal of oncology.

[37]  B. Bay,et al.  Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells. , 2009, Cancer letters.

[38]  Kenneth H. Buetow,et al.  PID: the Pathway Interaction Database , 2008, Nucleic Acids Res..

[39]  W. Birchmeier,et al.  Wnt signalling and its impact on development and cancer , 2008, Nature Reviews Cancer.

[40]  Manuela Gariboldi,et al.  Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma , 2008, Laboratory Investigation.

[41]  J. Brooks,et al.  Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. , 2007, Cancer research.

[42]  Amanda Y. Chan,et al.  Cell migration and invasion assays. , 2005, Methods.

[43]  A. Jayasurya,et al.  Metallothioneins in human tumors and potential roles in carcinogenesis. , 2003, Mutation research.

[44]  S. Theocharis,et al.  Metallothionein: A Multifunctional Protein from Toxicity to Cancer , 2003, The International journal of biological markers.

[45]  L. Fan,et al.  Potential role of p53 on metallothionein induction in human epithelial breast cancer cells , 2002, British Journal of Cancer.

[46]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[47]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[48]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[49]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.